Compare Enveric Biosciences Inc (ENVB) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.65 (market cap $7.77B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 1161.4× Enveric Biosciences Inc's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| ENVB | PDBC | |
|---|---|---|
Market Cap | $6.69M | $7.77B |
Volume | 41,141 | 4,055,996 |
Sector | Health | — |
52-Week High | $10.80 | $20.10 |
52-Week Low | $1.27 | $13.16 |
Typical Hold Time | 14 Days | 56 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PDBC trades at $19.41, down 0.26% with neutral technical signals from moving averages and oscillators. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by new institutional positions from firms like Arlington Capital and Advisortrust Partners.
The commodity ETF faces a complex outlook with potential upside from ongoing geopolitical tensions and defensive portfolio rotation, but risks include the sharp increase in short interest and commodity market volatility. Analyst sentiment remains cautiously optimistic given the fund's strong 2026 performance and defensive characteristics in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
